Search

Background: Indexed left ventricular end‐diastolic volume (LVEDVi) is a left ventricle (LV) size marker. The "Recommendations for Chamber Quantification" guideline was published in 2006 and updated in 2015. Although the previous guideline maintained uniform cutoff points for both men and women, the latest revision introduced new thresholds that vary between genders. We evaluated the extent of change in labeled indexed LV diastolic volumes in men and women following the adoption of the 2015 guideline. Methods: Data were extracted from a web‐based registry from March 2020 to October 2022. LV indexed volume variables were categorized on the basis of the 2006 and 2015 guidelines. Results: Among the 7598 individuals, the classification of LVEDVi differed in 910 (12.0%) individuals. In 213 (5.5%) female subjects, substantial reclassification (i.e., transitioning from normal to moderate LV enlargement to mild to severe LV enlargement) occurred on the basis of the 2015 guideline. All females classified as having moderately abnormal LVEDVi according to the 2006 guideline were reclassified as having severely abnormal LVEDVi according to the 2015 guideline. Age, LV ejection fraction (LVEF), and significant aortic regurgitation (AR) were common factors contributing to the observed discrepancy in both men and women. Significant mitral regurgitation (MR) and regional or global motion abnormality were correlated with the reclassification of LVEDVi to higher abnormal partitions only in women. Conclusion: The observed disparities underscore the importance of ongoing dedicated research to reassess the range of indexed echocardiographic parameters, considering various outcomes and differences in countries. [ABSTRACT FROM AUTHOR]

Herein, we have synthesized a microspherical nickel‐cobalt‐layered double hydroxides‐reduced graphene oxide composite (NiCo‐LDHs‐rGO) through a one‐step hydrothermal method and then used it as an adsorbent for the removal of Pb2+ from aqueous solutions. Fourier transform infrared spectrophotometry (FT‐IR), field emission scanning electron microscopy (FESEM), mapping elemental analysis, electron dispersive x‐ray spectroscopy (EDX), x‐ray diffraction analysis (XRD), and the Brunauer–Emmett–Teller (BET) method were used for the characterization of the adsorbent. Factors affecting the adsorption of Pb2+ ion such as solution pH, adsorbent dosage, contact time, competing ion, and regeneration were investigated in batch mode by the NiCo‐LDHs‐rGO. Under optimized conditions based on the Taguchi method (pH = 5.0, adsorbent dosage = 20 mg, and contact time = 30 min), the highest removal percentage was found to be 99.7% for 100 mg L−1 of Pb2+. According to the results, NiCo‐LDHs‐rGO exhibited a high preference for Pb2+ over Cu2+, Zn2+, and Cd2+. This adsorbent was regenerated for several cycles (using 0.01 M HCl) with no significant deterioration in performance. Analyses of the adsorption isotherm models revealed that the adsorption of Pb2+ follows Freundlich isotherm with a maximum adsorption capacity of 200 mg g−1. Also, the kinetic data confirmed that pseudo second order kinetic equation is the best model for predicting the kinetics. Furthermore, the Simulink modelling illustrated that the adsorption kinetics of Pb2+ onto NiCo‐LDHs‐rGO is done with high accuracy in a continuous stirred‐tank reactor. Finally, dual interactions of the effective parameters can be modelled by polynomial equations in MATLAB, and according to the Taguchi model, pH is clearly the most important feature among all effective parameters. [ABSTRACT FROM AUTHOR]

Cardiovascular disease is prevalent globally and is the most common complication of metabolic syndrome (MetS). Previous studies have suggested that curcumin and probiotics may improve the lipid profile, so we aimed to investigate the effects of the edible powder enriched with these substances on lipid profile level and atherogenic indices such as Atherogenic Coefficient (AC), Castelli Risk Index‐I (CRI‐I), Castelli Risk Index‐II (CRI‐II), and Atherogenic Index of Plasma (AIP). In the present parallel randomized double‐blinded placebo‐controlled clinical trial, 124 people with MetS with overweight or obesity were randomly allocated to 4 groups and were followed up for 8 weeks. The participants received a low‐calorie diet and a daily sachet of enriched powder drink. The sachets contained either 109 CFU of probiotics or 1 g of curcumin, or probiotic + curcumin (pro + cur), or placebo, respectively. The fasting lipid profile and atherogenic indices were measured at the beginning and end of the study. One hundred and fourteen participants completed the study. At the end of the study, the within‐ and between‐group comparisons showed no significant differences in lipid profile and atherogenic indices (p >.05). Based on the results of the current study, taking an oral powder containing 1 g curcumin and 109 CFU probiotics for 8 weeks had no effect on the lipid profile level and atherogenic indices; however, more studies are recommended. [ABSTRACT FROM AUTHOR]

This article discusses the production of therapeutic radiopharmaceuticals in Iran, specifically focusing on the transition from beta-emitting to alpha-emitting targeted radionuclide therapy (TRT). Iran has made significant advancements in producing diagnostic and therapeutic radiopharmaceuticals, with over 210 nuclear medicine centers and a strong foundation of human resources in the field. The recent manufacturing of alpha-emitting radiopharmaceuticals in Iran has shown promising prospects for TRT, particularly in the treatment of neuroendocrine tumors and metastatic prostate cancer. The use of alpha emitters in cancer treatment has gained interest due to their high radiotoxicity, but it requires specific measures for imaging, dosimetry, and radiation protection. Overall, alpha-emitting radionuclide therapy has the potential to become a significant strategy in cancer management. The document also provides a list of references to various scientific articles related to alpha-emitting targeted therapy, which can be valuable for researchers and healthcare professionals interested in the field. [Extracted from the article]